10.2.1 Drugs that enhance neuromuscular transmission

Anticholinesterases are used for myasthenia gravis Their muscarinic side effects, including bradycardia and an increase in sweating, salivary and gastric secretion and gastrointestinal and uterine motility, are all antagonised by atropine.

  • Tablets 60mg (£45.57 = 200 tablets)


  • Myasthenia gravis


  • 30–120mg at suitable intervals throughout day, total daily dose 0.3–1.2g
  • Granules for oral suspension 125mg, 250mg, 1000mg


  1. NICE HST3 Ataluren recommended for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (NHS England commissioned) (July 2016)
  • Solution for injection vials 12mg in 5ml


  1. NICE TA588: Nusinersen (Spinraza) is recommended as an option for treating 5q spinal muscular atrophy (SMA), only when the criteria of the NICE TA are met (July 2019)
  2. MHRA Drug Safety Update (September 2018): Nusinersen (Spinraza): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently

Not routinely funded for multiple sclerosis. See NHS England Clinical Commissioning Policy Statement: Fampridine for Multiple Sclerosis


Home > Formulary > Chapters > 10. Musculoskeletal & joint diseases > 10.2 Drugs used in neuromuscular disorders > 10.2.1 Drugs that enhance neuromuscular transmission


  • First line
  • Second line
  • Specialist
  • Hospital